A clinically useful and biologically informative genomic classifier for papillary thyroid cancer.
Steven Craig, Cynthia Stretch, Farshad Farshidfar, Dropen Sheka, Nikolay Alabi, Ashar Siddiqui, Karen Kopciuk, Young Joo Park, Moosa Khalil, Faisal Khan, Adrian Harvey, Oliver F Bathe
October 2023 Front Endocrinol (Lausanne)Synopsis of Social media discussions
The collective discussions showcase enthusiasm about the new genomic classifier, with phrases like 'clinically useful,' 'accurately determines risk,' and 'guide treatment' emphasizing the perceived practical impact. Posts mention the test 'Thyroid GuidePx®,' its development, and its potential to improve prognosis assessments, demonstrating high engagement and recognition of the publication's importance.
Agreement
Moderate agreementMost discussions express support and acknowledgment of the article's significance, highlighting the usefulness of the genomic classifier.
Interest
High level of interestThe posts demonstrate strong interest, with many sharing details about the test, its development, and potential clinical benefits.
Engagement
High engagementComments include references to the test's application, mentions of the research process, and calls to read the publication, indicating deep involvement.
Impact
High level of impactThe consensus suggests that this research could meaningfully influence thyroid cancer management and diagnostics, viewed as a notable advancement.
Social Mentions
YouTube
10 Videos
20 Posts
News
2 Articles
Metrics
Video Views
5,663
Total Likes
377
Extended Reach
205,025
Social Features
32
Timeline: Posts about article
Top Social Media Posts
Research Features
Oliver Bathe, CEO & Founder of @QualisureDx, developed a test that determines #RecurrenceRisk for papillary #thyroidcancer (PTC), called Thyroid GuidePx®.
DOI: https://t.co/6Vs4agpizD
Read our article: https://t.co/aYMMW54Y9Q
view full post
Qualisure Diagnostics Inc.
We are pleased to share the publication of our study on 742 #PapillaryThyroidCancer patients. This is the basis for #ThyroidGuidePx®, our new #MolecularTest that accurately determines the risk of recurrence.
Link here:
https://t.co/HMlFQxOOq1
#MedTwitter #EndoTwitter #ThyCa https://t.co/GwI1rYWxvv
view full post
Frontiers - Endocrinology
New Research: A clinically useful and biologically informative genomic classifier for papillary thyroid cancer: Clinical management of papillary thyroid cancer depends on estimations of prognosis. Standard care, which relies on… #Endocrinology #Endo https://t.co/2GMc0d4ZuU
view full post
Researchpod
Professor Oliver Bathe, CEO & Founder of @QualisureDx, along with colleagues at the University of Calgary, has developed Thyroid GuidePx® - a test to accurately predict #RecurrenceRisk of papillary #thyroidcancer.
DOI: https://t.co/XOE86gQ9WF
Listen: https://t.co/Ci0VrPHf21
view full post
Leslie Karras
Frontiers | A clinically useful and biologically informative genomic classifier for papillary thyroid cancer. Access the recent publication through the link below:
https://t.co/qUEqENKgvR #PapillaryThyroidCancer #Endocrinology #SaveYourThyroid https://t.co/YtM6WdOqMT
view full post
Posts referencing the article
Advances in Genetic Testing for Papillary Thyroid Cancer Risk Assessment
Decisions on treating papillary thyroid cancer depend on recurrence risk estimation. Professor Oliver Bathe and team developed the Thyroid GuidePx test, using genetic data to improve risk assessment by identifying three molecular subtypes for better treatment planning.
November 16, 2024
1,842 views
Advances in Molecular Testing for Personalized Thyroid Cancer Treatment
Explore how molecular tests are enhancing thyroid cancer diagnosis and personalized care, featuring insights from Dr. Oliver Bathe, CEO of Qualisure Diagnostics, on cutting-edge genomic classifiers and their impact on clinical decision-making.
November 23, 2023
675 views
Advances in Molecular Testing for Thyroid Cancer Diagnosis and Treatment
November 25, 2023
591 views
Advances in Thyroid Cancer Diagnosis and Personalized Treatment
Learn about thyroid cancer and recent developments in molecular testing to improve personalized treatment. Featured expert Dr. Oliver Bathe discusses innovative diagnostic solutions and clinical challenges in thyroid cancer care.
November 26, 2023
561 views
Molecular Testing Enhances Personalized Thyroid Cancer Treatment
Learn more about thyroid cancer in this playlist httpsyoutubecomplaylistlistPL5tSaOk33p79pNzI2Md7pYra2tE2xRZN0sicyNlSuaqYmN6w37W. Dr. Oliver Bathe, CEO of Qualisure Diagnostics, discusses how molecular tests help clinicians personalize treatment decisions for thyroid cancer patients, improving outcomes through advanced geno
November 24, 2023
429 views
Advances in Thyroid Cancer Diagnostics and Personalized Treatment Strategies
Learn more about thyroid cancer in this playlist. Dr. Oliver Bathe discusses innovative molecular tests that help oncologists personalize treatment, improving outcomes for patients with thyroid cancer.
November 21, 2023
393 views
Understanding Subtypes of Papillary Thyroid Cancer for Improved Diagnosis
Learn about thyroid cancer and the clinical significance of its subtypes in this informative video. Dr. Oliver Bathe discusses advances in molecular testing that aid in personalized treatment.
November 22, 2023
320 views
Advances in Personalized Treatment for Thyroid Cancer Using Genomic Profiling
Learn more about thyroid cancer in this playlist httpsyoutubecomplaylistlistPL5tSaOk33p79pNzI2Md7pYra2tE2xRZN0sicyNlSuaqYmN6w37W. Dr. Oliver Bathe discusses innovative molecular tests that enhance cancer care by guiding personalized treatment decisions based on genomic profiling.
November 22, 2023
303 views
Advances in Molecular Testing for Thyroid Cancer Treatment Optimization
Learn more about thyroid cancer in this playlist httpsyoutubecomplaylistlistPL5tSaOk33p79pNzI2Md7pYra2tE2xRZN0sicyNlSuaqYmN6w37W. Dr. Oliver Bathe discusses innovative molecular tests developed by Qualisure Diagnostics that help personalize cancer treatment through genomic classifiers, improving clinical decision-making.
November 28, 2023
285 views
Advances in Personalized Treatment for Thyroid Cancer Using Molecular Diagnostics
Learn about innovative molecular tests that improve thyroid cancer diagnosis and treatment, with insights from Dr. Oliver Bathe, CEO of Qualisure Diagnostics, on how technology personalizes cancer care.
November 27, 2023
264 views
-
RT @QualisureDx: We are pleased to share the publication of our study on 742 #PapillaryThyroidCancer patients. This is the basis for #Thyro…
view full postFebruary 5, 2025
2
-
Researchpod
@ResearchpodHQ (Twitter)Professor Oliver Bathe, CEO & Founder of @QualisureDx, along with colleagues at the University of Calgary, has developed Thyroid GuidePx® - a test to accurately predict #RecurrenceRisk of papillary #thyroidcancer. DOI: https://t.co/XOE86gQ9WF Listen: https://t.co/Ci0VrPHf21
view full postDecember 18, 2024
1
-
Richard S
@Richard01173388 (Twitter)Oliver Bathe, CEO and Founder of Qualisure Diagnostics, developed a test that determines recurrence risk for papillary thyroid cancer (PTC), called Thyroid GuidePx®. Read our article: https://t.co/bIQkJpt5iI DOI: https://t.co/AIrSK6kKHJ
view full postNovember 21, 2024
1
-
Luis Alberto Luengo
@luengo1958 (Twitter)RT @ResearchFeature: Oliver Bathe, CEO & Founder of @QualisureDx, developed a test that determines #RecurrenceRisk for papillary #thyroidca…
view full postNovember 17, 2024
23
-
Research Features
@ResearchFeature (Twitter)Oliver Bathe, CEO & Founder of @QualisureDx, developed a test that determines #RecurrenceRisk for papillary #thyroidcancer (PTC), called Thyroid GuidePx®. DOI: https://t.co/6Vs4agpizD Read our article: https://t.co/aYMMW54Y9Q
view full postNovember 17, 2024
294
23
-
Leslie Karras
@LKarras (Twitter)RT @LKarras: Frontiers | A clinically useful and biologically informative genomic classifier for papillary thyroid cancer. Access the recen…
view full postAugust 7, 2024
1
-
Leslie Karras
@LKarras (Twitter)Frontiers | A clinically useful and biologically informative genomic classifier for papillary thyroid cancer. Access the recent publication through the link below: https://t.co/qUEqENKgvR #PapillaryThyroidCancer #Endocrinology #SaveYourThyroid https://t.co/YtM6WdOqMT
view full postJuly 14, 2024
1
1
-
Leslie Karras
@LKarras (Twitter)A clinically useful and biologically informative genomic classifier for papillary thyroid cancer https://t.co/G930Yrc7R0 #endocrinology #thyroid #endo #PapillaryThyroidCancer #PTC
view full postMarch 27, 2024
-
Save Your Thyroid with Jen
@SaveYourThyroid (Twitter)Three subtypes of #papillarythyroidcancer #podcast https://t.co/YadurY4Ees via @YouTube @QualisureDx
view full postNovember 24, 2023
-
Save Your Thyroid with Jen
@SaveYourThyroid (Twitter)A tool to guide #thyroidcancer treatment https://t.co/3EySxpnljw via @YouTube @QualisureDx
view full postNovember 24, 2023
-
Save Your Thyroid with Jen
@SaveYourThyroid (Twitter)Do you know these #FACTS about #papillarythyroidcancer? https://t.co/ctURhObgW0 via @YouTube @QualisureDx #cancerispersonal #moleculartesting
view full postNovember 21, 2023
-
Chidambara .ML.
@chidambara09 (Twitter)RT @QualisureDx: We are pleased to share the publication of our study on 742 #PapillaryThyroidCancer patients. This is the basis for #Thyro…
view full postOctober 18, 2023
2
-
Qualisure Diagnostics Inc.
@QualisureDx (Twitter)We are pleased to share the publication of our study on 742 #PapillaryThyroidCancer patients. This is the basis for #ThyroidGuidePx®, our new #MolecularTest that accurately determines the risk of recurrence. Link here: https://t.co/HMlFQxOOq1 #MedTwitter #EndoTwitter #ThyCa https://t.co/GwI1rYWxvv
view full postOctober 18, 2023
8
2
-
Qualisure Diagnostics Inc.
@QualisureDx (Twitter)RT @CynStre: Check out our work from @QualisureDx on #thyroidcancer #prognosis A clinically useful and biologically informative genomic cl…
view full postSeptember 28, 2023
1
-
Cynthia Stretch
@CynStre (Twitter)Check out our work from @QualisureDx on #thyroidcancer #prognosis A clinically useful and biologically informative genomic classifier for papillary thyroid cancer https://t.co/uqXG2zsXjh
view full postSeptember 13, 2023
1
-
Cynthia Stretch
@CynStre (Twitter)RT @FrontEndocrinol: New Research: A clinically useful and biologically informative genomic classifier for papillary thyroid cancer: Clinic…
view full postSeptember 13, 2023
1
-
Frontiers - Endocrinology
@FrontEndocrinol (Twitter)New Research: A clinically useful and biologically informative genomic classifier for papillary thyroid cancer: Clinical management of papillary thyroid cancer depends on estimations of prognosis. Standard care, which relies on… #Endocrinology #Endo https://t.co/2GMc0d4ZuU
view full postSeptember 12, 2023
1
1
-
bioRxivbot
@BiorxivB (Twitter)A Clinically Useful and Biologically Informative Genomic Classifier for Papillary Thyroid Cancer https://t.co/byIKpLUXp7
view full postDecember 31, 2022
-
minnlab_litbot
@MLitbot (Twitter)A Clinically Useful and Biologically Informative Genomic Classifier for Papillary Thyroid Cancer https://t.co/rqPz5zOeDI
view full postDecember 30, 2022
-
bioRxiv
@biorxivpreprint (Twitter)A Clinically Useful and Biologically Informative Genomic Classifier for Papillary Thyroid Cancer https://t.co/R9eqxSh7b1 #bioRxiv
view full postDecember 30, 2022
Abstract Synopsis
Jona
@LondoncVosx (Twitter)